SB 262: INSPECT program. - Indiana

Enrolled Senate Bill (S) → Senate Bill (S) · 4 edits

MODERATE

SB 262 updates the Indiana Code to clarify who counts as a 'dispenser' under the INSPECT prescription monitoring program and expands who can access confidential drug data. The bill adds a specific exemption for veterinary practitioners dispensing controlled substances and broadens the list of government officials who can receive patient data for investigations.

Scope change

The bill expands the scope of the INSPECT program by including veterinary practitioners in the definition of dispensers and adding the Office of the Secretary of Family and Social Services as an entity authorized to receive confidential data.

ELIGIBILITY

Veterinary practitioners are now explicitly included as dispensers who must report controlled substance transactions to the INSPECT program.

ENFORCEMENT

The Office of the Secretary of Family and Social Services is added to the list of entities authorized to receive confidential prescription data for investigations.

DEFINITION

The definition of 'dispense' was amended to clarify that it does not apply to drugs administered directly to a patient or those dispensed by veterinary practitioners within a 72-hour supply limit.

REQUIREMENT

The bill reorganized the statute to align with the latest legislative session, updating references and clarifying the transmission of data requirements.

Engrossed Senate Bill (H) → Enrolled Senate Bill (S) · 5 edits · Mar 5, 2026

MODERATE

This bill transitions the legislative text from a draft Senate Bill to an enrolled Act, confirming its passage and final legal status. It defines specific circumstances under which pharmacies are exempt from reporting certain controlled substance data to the state monitoring program and clarifies exactly what data the state can share with health and social services agencies.

Scope change

The bill's scope remains focused on the Indiana Prescription Drug Monitoring Program (INSPECT), but the enrolled version provides final, legally binding definitions and reporting requirements that differ slightly from the draft regarding transmission deadlines and data sharing specifics.

DEFINITION

The definition of 'dispense' was finalized to explicitly include prescribing, administering, packaging, labeling, or compounding necessary to prepare a substance for delivery.

A new definition was added for 'prescription drug monitoring program data,' specifying that it includes reports on poisonings/overdoses and participation in opioid treatment programs.

REQUIREMENT

The deadline for submitting dispensing data to the INSPECT program was clarified to require transmission by the end of the next business day, with a specific exception for pharmacists who also prescribe.

New restrictions were added requiring pharmacists to verify the identity of anyone picking up controlled substances if they do not personally know the individual.

TECHNICAL

The document format changed from a draft bill with committee history to an enrolled act with final printing codes, indicating the bill has been signed into law.

Introduced Senate Bill (S) → Engrossed Senate Bill (H) · 3 edits · Feb 25, 2026

MINOR

This bill updates the definition of 'dispense' to clarify that it does not include drugs administered directly to patients or dispensed by practitioners in small quantities (up to 72 hours). It also redefines 'prescription drug monitoring program data' to include participation in opioid treatment programs and expands the circumstances under which the board of pharmacy can share data with health and social services officials.

Scope change

The bill broadens the scope of the INSPECT program by explicitly exempting direct patient administration and small veterinary prescriptions from reporting requirements, while simultaneously expanding the types of data that can be shared with external agencies.

DEFINITION

The definition of 'dispense' was modified to explicitly exclude drugs administered directly to a patient and drugs dispensed by a practitioner in quantities of 72 hours or less.

The definition of 'prescription drug monitoring program data' was modified to add 'participation in an opioid treatment program' as reportable information.

REQUIREMENT

The bill was amended to reference a different prior law (P.L.17-2021) regarding the monitoring program requirements, indicating a change in the legislative history or foundation of the current rules.

INSPECT program.

What changed between versions

How they voted

Actions timeline

Sponsors